Parenteral Drugs (India) has rallied over 8% to Rs 129 after the company said Goa Formulations Limited, a subsidiary company has sold its pharmaceutical manufacturing unit at Goa to Fresenius Kabi India Private Limited for a total consideration of Rs 200 crore.
“The subsidiaries of the company M/s. Goa Formulations Limited has executed an agreement with M/s. Fresenius Kabi India Private Limited to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs 200 crore,” Parenteral Drugs India said in a regulatory filing.
Parenteral Drugs (India) Ltd is the holding company of Goa Formulations Limited.
The stock opened at Rs 129 and hit a 52-week high of Rs 131 on BSE. Around 32,400 shares have changed hands on both the counters on BSE and NSE
“The subsidiaries of the company M/s. Goa Formulations Limited has executed an agreement with M/s. Fresenius Kabi India Private Limited to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs 200 crore,” Parenteral Drugs India said in a regulatory filing.
Parenteral Drugs (India) Ltd is the holding company of Goa Formulations Limited.
The stock opened at Rs 129 and hit a 52-week high of Rs 131 on BSE. Around 32,400 shares have changed hands on both the counters on BSE and NSE
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%